司法程序和行政程序並行下的藥品專利鏈接制度--《專利法》第七十六條認識談

Patent Linkage System Under Judicial and Administrative Procedures--Comments on Article 76 of the Patent Law

此前圍遶我國藥品專利鏈接制度建立週程中的諸多法律争議,隨着《專利法》第七十六條對相關問題的明確而塵埃落定,由此也標誌着這一制度得到了我國立法機關的認可,希望籍此“提昇製藥行業創新能力”。作爲藥品專利鏈接制度的肇始地,“美國實施專利鏈接制度以來,美國的專利藥和仿製藥均得到較好的發展,很好地平衡了專利藥企和彷製藥企業的利益關係,仿製藥的處方量已經估到全國處方量90%左右”.

Numerous legal debates over the patent linkage system in China during its establishment had been settled as Article 76 of the China*s Patent Law clarifies its structure.This also indicated that the patent linkage system has been endorsed by the legislature in China,hoping to“enhance the innovative capability of the pharmaceutical industry”.As the birthplace of the patent linkage system,"the U.S.has implemented the patent linkage system.Ever since,both patented drugs and generic drugs in the U.S.have undergone great development,the interests between brand-name companies and generic companies have been well balanced and generic drug prescriptions accounted for about 90%of the prescriptions nationwide."